Skip to main content
. 2022 Jul 28;13:377. doi: 10.1186/s13287-022-03023-7

Fig. 4.

Fig. 4

Establishing MLOs from human iPSCs is improved by HFF. A Representative bright-field images of MLOs generated from human iPSCs with (lower panel) or without HFF (upper panel) at day 30. Bar, 50 μm. B Branching ratios of MLOs and MLOs-HFF. C Representative immunofluorescence images of MLOs and MLOs-HFF at day 30. Bar, 100 μm. D Sizes of MLOs and MLOs-HFF at different days. Day 10: MLOs (n = 136), MLOs-HFF (n = 107); day 17: MLOs (n = 131), MLOs-HFF (n = 121); day 25: MLOs (n = 83), MLOs-HFF (n = 84); day 30: MLOs (n = 66), MLOs-HFF (n = 78). E Percentage of large organoids (diameter > 200 μm) of MLOs and MLOs-HFF at day 30. F Representative hematoxylin and eosin staining of MLOs and MLOs-HFF at day 30 (left); percentage of organoids displaying duct-like structure in MLOs (n = 13) and MLOs-HFF (n = 39) at day 30 (right). G Representative immunohistochemical staining of MLOs and MLOs-HFF at day 30. Two-tailed Student t test, *p < 0.05, **p < 0.01, ***p < 0.001